The ADC binds Trop-2 on tumor cells, is internalized, and releases SN-38, which inhibits DNA topoisomerase I to cause DNA damage and apoptosis. Topoisomerase I is the intracellular pharmacologic target, not the antigen that directs cell-specific killing.